Spago Nanomedical
0,342 SEK +17,93%Vær den første som følger denne virksomhed
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Omsætning
1,2 mio.
EBIT %
-3.589,17 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPAGO
Daglig lav / høj pris
0,311 / 0,421
SEK
Markedsværdi
76,85 mio. SEK
Aktieomsætning
412,17 t SEK
Volumen
1,1 mio.
Finanskalender
Delårsrapport
02.05.2024
Generalforsamling
10.06.2024
Delårsrapport
21.08.2024
Delårsrapport
06.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Peter Lindell | 40,5 % | 40,5 % |
Mikael Lönn | 8,5 % | 8,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Spago Nanomedical strengthens management with Head of CMC & Supply
BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding"
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools